arrow_back Back to App

Increased Cancer Research Funding and Drug Shortage Study

This act aims to boost funding for cancer research by the National Cancer Institute to better align with cancer mortality rates. It also mandates a study into the causes of cancer drug shortages, which could improve access to treatments for patients.
Key points
Increases the National Cancer Institute's budget for cancer research by 25% annually for five years (2024-2028) compared to 2022.
Mandates a study into the reasons for cancer drug shortages, including economic issues, supply chain failures, and approval delays.
The report on drug shortages will include recommendations, potentially ensuring consistent access to vital therapies.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_HR_6807
Sponsor: Rep. Fitzpatrick, Brian K. [R-PA-1]
Process start date: 2023-12-14
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

KO Cancer Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_HR_6807.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2023-12-14.

What are the main provisions?

Key points include:

  • Increases the National Cancer Institute's budget for cancer research by 25% annually for five years (2024-2028) compared to 2022.
  • Mandates a study into the reasons for cancer drug shortages, including economic issues, supply chain failures, and approval delays.
  • The report on drug shortages will include recommendations, potentially ensuring consistent access to vital therapies.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Fitzpatrick, Brian K. [R-PA-1].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-25.

CATEGORIES

Health